(Nasdaq: INM) Triggers Monday's Radar With 5 Explosive Potential Catalysts (Low Float)

The cost and urgency surrounding neurodegenerative diseases

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on Behalf of InMed Pharmaceuticals Inc. (Nasdaq: INM) Triggers Monday's Radar With 5 Explosive Potential Catalysts (Low Float) *Click Here To Get Our Alerts Faster Via SMS* March 23rd Dear Reader, The cost and urgency surrounding neurodegenerative diseases have never been higher, and one organization is taking a bold step forward to confront that complexity head-on. In 2025 alone, the combined payments for healthcare, long-term care, and hospice services for people 65 and older living with dementia climbed to roughly $384Bn. That staggering number highlights not only how widespread the issue has become but also how much room there is for real progress. This company has chosen to approach cognitive decline from a different angle, charting new territory to enhance patient results and reimagine what treatment can look like. Its developments so far suggest that it could play a defining role in the field. With under 3.5Mn shares in its float and a major pharmaceutical development programs update, this Nasdaq profile has quickly earned a top spot on my watchlist: InMed Pharmaceuticals Inc. (Nasdaq: INM) InMed Pharmaceuticals is a pharmaceutical drug development company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. Alzheimer's is a subset of dementia that impacts the part of the brain that controls thought, memory and language and leads to increased morbidity and mortality. The two most recognized hallmarks of Alzheimer’s disease are the build-up of amyloid-beta plaques and neurofibrillary tangles caused by tau proteins. Emerging research indicates that the associated neuroinflammation is also a factor. Studies presented at AAIC 2025 further highlight neuroinflammation as a key contributor to disease progression and a promising therapeutic target. Lifestyle and genetics are likely contributors to disease development. Overview & Highlights - Important Details On InMed Pharmaceuticals InMed has two key pharmaceutical programs – including preclinical programs in Alzheimer’s disease and age-related macular degeneration. InMed’s small molecule compounds are demonstrating promising effects with potentially multiple mechanisms. INM-901 Demonstrates Positive Impacts on AD Pathologies INM-901 significantly reduces neuroinflammation in preclinical studies InMed’s INM-901 is a small-molecule, orally-available drug candidate being developed for Alzheimer’s disease. Promising studies demonstrate INM-901’s ability to reduce neuroinflammatory markers associated with Alzheimer’s disease.  In a recent Alzheimer’s disease ex vivo preclinical study, INM-901 significantly reduced neuroinflammation, a recognized contributor to Alzheimer’s disease development and progression. Important Study Findings: INM-901 significantly reduced levels of NLRP3 and IL-1β, two inflammasome markers increasingly implicated in the pathogenesis of Alzheimer’s disease and other neuroinflammatory diseases. INM-901 treatment resulted in a dose-dependent and statistically significant reduction in several key pro-inflammatory markers, including IL-6, IL-1β, KC/Gro, and IL-2. INM-901 reduced key pro-inflammatory markers, independent of amyloid-beta or tau pathology, signifying potential to treat other dementia-related diseases. ----- INM-901 - Targeting Initiation of Phase 1 Clinical Trial in Alzheimer’s Disease in 2027 InMed is accelerating development of its Alzheimer’s disease program. 2026 Development Priorities for INM-901 include: Conduct a pre-IND meeting with the U.S. Food and Drug Administration in Q3/2026. Continue to execute on IND-enabling pharmacology and toxicology studies. Continued development and scale up of drug substance and product manufacturing activities to support IND enabling studies and submission. Engage regulatory / clinical experts to map out topline clinical design for first in human clinical trials for the INM-901. Subject to regulatory feedback and completion of IND-enabling activities, the Company targets submission of an IND and initiation of a Phase 1 clinical trial in 2027. Age-related macular degeneration (AMD) is an eye disease that causes damage to the macula which is part of the retina at the back of the eye. The macula controls the sharp vision straight ahead of you, and damage to the macula affects a person’s central vision. AMD is common amongst the elderly and is a leading cause of vision loss. While it does not cause complete blindness, those with AMD will find it difficult to read, drive or do simple things around the home. There two primary types of AMD – dry AMD and wet AMD. Dry AMD is the most common form of AMD, accounting for 80% of AMD cases. Dry AMD typically takes several years to progress and happens in three stages. The advanced stage of dry AMD is also referred to as geographic atrophy (GA). InMed’s INM-089 is being studied for dry AMD. INM-089 for Age-Related Macular Degeneration InMed has selected INM-089, a small molecule drug candidate, for further preclinical development. Recent preclinical studies of INM-089 demonstrated significant functional and pathological improvements in an AMD disease study model. Results from several in vitro and in vivo studies demonstrate INM-089’s pharmacological effects in the potential treatment of dry AMD, as summarized: INM-089 provides neuroprotection of photoreceptors and improves photoreceptor function INM-089 improves the integrity of the retinal pigment epithelium (RPE) INM-089 reduces extracellular autofluorescent (AF) deposits, a hallmark of dry AMD INM-089 preserves retinal function in the back of the eye INM-089 improves thickness of “outer nuclear layer” (ONL) of the retina where photoreceptors are located. Based on widely accepted ocular research, the thickness of the outer nuclear layer is strongly correlated with photoreceptor preservation and visual acuity. InMed is completing preclinical studies, including dose-ranging assessment studies, in preparation for a pre-IND meeting with the FDA in Q4 2026. Pharmaceutical Pipeline - InMed Pharmaceuticals Inc. Find More Details And Sources Here: INM's Website. INM's Presentation. ----- 5 Key Potential Catalysts Put (Nasdaq: INM) On Our Radar Monday 1.) A Float Of This Size May Contribute To Increased Volatility. According to Yahoo Finance, the website is reporting INM to have a float of under 3.5Mn shares. 2.) Strategic FDA Pre-IND Engagement For INM-901 Could Signal Readiness To Advance Toward Clinical Trials. InMed’s anticipated pre-IND meeting with the U.S. FDA in Q3 2026 represents a key milestone for its Alzheimer’s disease program. This meeting could clarify the regulatory pathway, determine Phase 1 trial design, and validate the preclinical package that highlights INM-901’s unique neuroinflammation-targeting mechanism. With Alzheimer’s treatments shifting toward multi-pathway approaches, the FDA’s preliminary feedback could draw serious attention, validate the drug’s commercial potential, and position InMed as a serious contender among next-generation neuroinflammation-focused therapeutics. 3.) INM-901 Phase 1 Clinical Trial Pathway Alignment Sets Stage For 2027 First-In-Human Study Launch. Momentum is building around InMed’s target to initiate a Phase 1 clinical trial of INM-901 in Alzheimer’s disease in 2027, and confirmation of alignment between preclinical success and regulatory progress could be a pivotal catalyst. 4.) Groundbreaking INM-901 Neuroinflammation Data Reinforces Scientific Leadership In Multifactorial Alzheimer’s Therapeutics. InMed’s release of new preclinical data showing robust anti-neuroinflammatory and neuroprotective activity for INM-901 could serve as a powerful catalyst, validating the company’s distinctive scientific platform. Demonstrating measurable reductions in key inflammatory biomarkers (including IFN-γ, TNF-α, and IL-1β) alongside improvements in neuronal growth and behavioral outcomes strengthens INM-901’s profile as a multifactorial solution to Alzheimer’s disease. These results not only diversify InMed’s scientific narrative beyond single-target mechanisms but also align with emerging research consensus. 5.) Advancement Of INM-089 Toward FDA Pre-IND Meeting Could Ignite Interest In The Ophthalmology Market. InMed’s progress with INM-089, including successful dose-ranging studies and advancement toward a pre-IND meeting in Q4 2026, may attract increased attention from watchers of the dry age-related macular degeneration (AMD) space. As current treatment options are limited, INM-089’s potential to address this underserved market positions InMed in a multi-Bn-dollar therapeutic category. Clear evidence of dose proportionality and pharmacologically relevant exposure underpins regulatory readiness. A strong FDA feedback outcome could establish a second clinical-ready asset for the company, diversifying risk and showcasing InMed’s expanding expertise beyond neurology into ophthalmology. ----- The company’s 2026 milestones—ranging from IND-enabling studies and formulation scale-up to engagement with regulatory experts—are converging on this inflection point.  A formally communicated timeline or partnership announcement for clinical execution could validate years of groundwork. As the program transitions from laboratory to human trials, industry enthusiasm could surge around the company’s novel approach. Coverage is officially underway on InMed Pharmaceuticals Inc. (Nasdaq: INM). As soon as update are available, we'll get them out to you quickly. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/22/2026 and ending on 03/23/2026 to publicly disseminate information about (INM:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid forty five thousand USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (INM:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/inm-9zcxw/#details

Fierce Investor | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice